These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 362528)
1. Antiserum treatment of gram-negative bacteremia. Braude AI; Ziegler EJ; McCutchan JA Schweiz Med Wochenschr; 1978 Dec; 108(48):1872-6. PubMed ID: 362528 [TBL] [Abstract][Full Text] [Related]
2. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708 [TBL] [Abstract][Full Text] [Related]
3. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. Braude AI; Ziegler EJ; Douglas H; McCutchan JA J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776 [TBL] [Abstract][Full Text] [Related]
4. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia. McCutchan JA; Wolf JL; Ziegler EJ; Braude AI Schweiz Med Wochenschr Suppl; 1983; 14():40-5. PubMed ID: 6361990 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Dunn DL; Ferguson RM Surgery; 1982 Aug; 92(2):212-9. PubMed ID: 7048594 [TBL] [Abstract][Full Text] [Related]
7. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin. Ziegler EJ; McCutchan JA; Braude AI Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063 [No Abstract] [Full Text] [Related]
8. [Anti-endotoxin core glycolipid antibody: the preparation of immune serum of E. Coli J5]. Xu XN; Li ZJ; Li YP Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Jun; 16(6):358-60. PubMed ID: 15182450 [TBL] [Abstract][Full Text] [Related]
9. Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia. McCutchan JA; Ziegler EJ; Braude AI Eur J Cancer (1965); 1979; 15 Suppl():77-80. PubMed ID: 397064 [No Abstract] [Full Text] [Related]
10. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Calandra T; Baumgartner JD; Glauser MP Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424 [TBL] [Abstract][Full Text] [Related]
11. Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides. Ziegler EJ; Douglas H; Braude AI J Clin Invest; 1973 Dec; 52(12):3236-8. PubMed ID: 4584346 [TBL] [Abstract][Full Text] [Related]
12. Immunization against nosocomial infection. Braude AI; Ziegler EJ; McCutchan JA; Douglas H Am J Med; 1981 Feb; 70(2):463-6. PubMed ID: 7008592 [TBL] [Abstract][Full Text] [Related]
13. Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Ziegler EJ; McCutchan JA; Douglas H; Braude AI Trans Assoc Am Physicians; 1975; 88():101-8. PubMed ID: 772922 [TBL] [Abstract][Full Text] [Related]
14. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria. Trautmann M; Hahn H Infection; 1985; 13(3):140-5. PubMed ID: 3897069 [TBL] [Abstract][Full Text] [Related]
15. Functional role of antibody against "core" glycolipid of Enterobacteriaceae. Young LS; Stevens P; Ingram J J Clin Invest; 1975 Oct; 56(4):850-61. PubMed ID: 1099119 [TBL] [Abstract][Full Text] [Related]
16. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067 [TBL] [Abstract][Full Text] [Related]
17. Release of gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5. Hellman J; Loiselle PM; Zanzot EM; Allaire JE; Tehan MM; Boyle LA; Kurnick JT; Warren HS J Infect Dis; 2000 Mar; 181(3):1034-43. PubMed ID: 10720528 [TBL] [Abstract][Full Text] [Related]
18. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms. Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370 [TBL] [Abstract][Full Text] [Related]
19. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. Cross AS; Opal SM; Warren HS; Palardy JE; Glaser K; Parejo NA; Bhattacharjee AK J Infect Dis; 2001 Apr; 183(7):1079-86. PubMed ID: 11237833 [TBL] [Abstract][Full Text] [Related]